XML 97 R77.htm IDEA: XBRL DOCUMENT v3.6.0.2
Equity Incentive Program - Stock Options and SSARs (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Document Fiscal Year Focus 2016    
SSARs, Number of Shares (in shares):      
Forfeited 0    
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
Dividend yield 0.00%    
Expected life (years) 4 years 6 months 4 years 6 months  
SSARs, Weighted-average grant date fair value (in dollars per share):      
Granted $ 11.20    
Stock Options, Number of Shares (in share):      
Beginning balance 3,165,556    
Granted 2,038,013    
Exercised 0    
Forfeited (410,959)    
Expired (108,493)    
Ending balance 4,684,117 3,165,556  
Exercisable 938,890    
Stock Options, Weighted Average Exercise Price (in dollars per share):      
Beginning balance $ 22.58    
Granted 11.20    
Exercised 0.00    
Forfeited 18.15    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 22.22    
Ending balance 18.03 $ 22.58  
Exercisable $ 22.67    
SARS and Options, Additional Disclosures      
Options, aggregate intrinsic value, outstanding $ 10,400    
Options, aggregate intrinsic value, exercisable $ 0    
Options, weighted average remaining contractual term, outstanding 5 years 6 months    
Options, weighted average remaining contractual term, exercisable 5 years    
Unrecognized compensation expense $ 12,000    
Weighted average period for compensation expense to be recognized 1 year 2 months    
SSARs and Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
Dividend yield   0.00% 0.00%
SSARs      
SSARs, Number of Shares (in shares):      
Beginning balance 1,013,780    
Granted 0    
Exercised (56,707)    
Expired (58,355)    
Ending balance 898,718 1,013,780  
Exercisable 898,718    
SSARs, Weighted-average grant date fair value (in dollars per share):      
Beginning balance $ 20.92    
Granted 0.00    
Exercised 14.50    
Forfeited 0.00    
Expired 22.06    
Ending balance 21.25 $ 20.92  
Exercisable 21.25    
Stock Options, Weighted Average Exercise Price (in dollars per share):      
Granted $ 0.00    
SARS and Options, Additional Disclosures      
SSARs, aggregate intrinsic value, outstanding $ 500    
SSARs, aggregate intrinsic value, exercisable $ 500    
SSARs, weighted average remaining contractual terms, outstanding 4 years 11 months    
SSARs, weighted average remaining contractual term, exercisable 4 years 11 months    
Unrecognized compensation expense $ 0    
Minimum | Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
Risk-free interest rate 1.04% 1.24% 1.32%
Volatility 37.00% 39.80% 42.90%
Fair value at date of grant $ 3.76 $ 5.94 $ 7.99
Minimum | SSARs and Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
Expected life (years)     4 years 6 months
Maximum | Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
Risk-free interest rate 1.25% 1.50% 1.70%
Volatility 39.60% 42.40% 49.90%
Fair value at date of grant $ 4.83 $ 6.88 $ 13.50
Maximum | SSARs and Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]      
Expected life (years)     5 years 3 months 29 days